LFST vs TDOC: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
LFST is the larger of the two ($5.55B market cap): the incumbent the market prices for continued execution (33.87x forward earnings, beta 1.30). TDOC is the smaller challenger ($1.58B), priced similarly on forward earnings (-15.60x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
LFST vs TDOC: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | LFST | TDOC | What it tells you |
|---|---|---|---|
| Market cap | $5.55B | $1.58B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 33.87 | -15.60 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.30 | 1.97 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 89% of range | 77% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 3.72 | 1.22 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how LFST and TDOC affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LFST and TDOC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LFST and TDOC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does LifeStance Health Group (LFST) do?
LifeStance Health Group runs outpatient mental healthcare at national scale. Founded in 2017 and public since June 2021, the company employs licensed therapists, psychologists, psychiatrists and psychiatric nurse practitioners through its subsidiaries and supported practices, then routes patients to them through in-network insurance relationships. Care is delivered both in person and virtually, from more than ~550 centers spread across ~33 states, and volume reached roughly ~2.6 million patient visits in the second quarter of 2026 alone. Unlike cash-pay teletherapy apps, LifeStance is built around commercial insurance: about ~88% of revenue comes from commercial payors, ~7% from government programs and ~4% from self-pay, which means reimbursement rates negotiated with health plans, not consumer subscription pricing, set the revenue line.
What does Teladoc Health (TDOC) do?
Teladoc Health makes money through two reporting segments. Integrated Care sells virtual-care services (general medical, chronic-condition management for diabetes and hypertension via the former Livongo programs, expert medical opinions, and licensable platform tools) mostly to employers, health plans, and hospitals on a per-member-per-month and visit-fee basis; in 2025 it was the larger and more profitable engine, with Q2 2026 revenue of about $394 million and a 16.5% adjusted EBITDA margin. BetterHelp is a direct-to-consumer online mental-health and therapy subscription brand whose paying-member count and revenue have been falling; BetterHelp revenue declined about ~9% to roughly ~$950 million in 2025 and its segment adjusted EBITDA fell about ~46% to roughly ~$42 million as marketing costs rose, prompting a pivot toward insurance-reimbursed therapy.
LFST vs TDOC: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- LFST drivers: Clinician headcount plus productivity, compounding together; Operating leverage on a largely fixed center and corporate base.
- TDOC drivers: Integrated Care and chronic-condition management; Free cash flow and balance-sheet discipline.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Payor concentration is the sharpest exposure: two commercial insurers each represented roughly ~14% to ~15% of revenue, so a single unfavorable contract renegotiation or a reimbursement policy shift can compress the rate per visit that drives margin expansion. For TDOC, revenue has been roughly flat to declining for several years, and total revenue fell about 2% in 2025 and about 4% in Q2 2026, so the turnaround is about stabilization rather than growth.
LFST or TDOC: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick LFST if you believe its drivers more; TDOC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LFST and TDOC guides.
LFST vs TDOC: the full fundamentals
LFST. Pricing reflects the inflection rather than the trailing profit: the shares are up ~72% in 2026, yet forward earnings estimates (~$0.36 for 2026, ~$0.43 for 2027) put the multiple near ~28x rather than the ~92x trailing GAAP figure, and the gap is mostly stock compensation, amortization and litigation costs. Against full-year 2026 adjusted EBITDA guidance of ~$215M to ~$235M, enterprise value works out to roughly ~21x the midpoint. Cash of ~$226M against ~$276M of term loan principal leaves the balance sheet close to neutral, and analysts' mean target sits near ~$14.40 with a buy consensus.
TDOC. As of October 16, 2026, Teladoc trades at about 0.4 times trailing sales and below book value, a valuation that prices in continued revenue decline rather than a turnaround. With GAAP losses ongoing, adjusted EBITDA and free cash flow remain the practical yardsticks, and the $130 to $170 million free cash flow guide equals a large share of the roughly $1.1 billion market cap. Analysts rate it hold on average, with a mean target near $7.59 across 17 firms.
Headline figures (approximate, October 2026): LFST shows revenue (ttm) ~$1.58B (Q2 2026 +26% YoY), net income (ttm) ~$51M, or ~$0.13 per share, gross / operating margin ~34% / ~7%, free cash flow (ttm) ~$172M; TDOC shows revenue (ttm) ~$2.49 billion; Q2 2026 revenue $606.9 million, down ~4% YoY, segment mix (q2 2026) Integrated Care $394.3 million (+1%); BetterHelp $212.6 million (-12%), adjusted ebitda Q2 2026 $65.7 million; FY2026 guidance $271 to $303 million, net income (ttm) ~-$177 million (GAAP loss); Q2 2026 EPS -$0.21 vs ~-$0.22 expected.
The bottom line: LFST vs TDOC
LFST and TDOC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LFST and TDOC exposure against your real portfolio. It is not an investment adviser.
Wondering how LFST or TDOC fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about LifeStance Health Group
Ask Walnut's AI anything about LFST and see how it fits what you own.
FAQ
What is the difference between LFST and TDOC?
+
LifeStance Health Group runs outpatient mental healthcare at national scale. Teladoc Health makes money through two reporting segments. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is LFST or TDOC the better stock?
+
Neither is universally better. LFST is the larger incumbent; TDOC is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, LFST or TDOC?
+
On forward P/E (as of November 2026), LFST trades at 33.87x and TDOC at -15.60x, so TDOC is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both LFST and TDOC?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of LFST vs TDOC?
+
LFST: Payor concentration is the sharpest exposure: two commercial insurers each represented roughly ~14% to ~15% of revenue, so a single unfavorable contract renegotiation or a reimbursement policy shift can compress the rate per visit that drives margin expansion. Valuation leaves little cushion after a ~138% one-year run, with the stock near ~92 times trailing earnings, ~28 times forward earnings and ~37 times EV to EBITDA on a business whose GAAP net margin is about ~3%, meaning a growth deceleration toward the ~11% pace of 2025 would be poorly received. Legal and regulatory matters are ongoing rather than resolved: a privacy class action captioned Strong v. LifeStance Health Group, filed April 26, 2023 over the use of website pixel tracking technologies, is settling for roughly ~$3.0 million with a final approval hearing scheduled for October 2026 (the outcome was not yet reported in the sources reviewed for this October 16 update), and the June 2021 IPO drew a securities class action in 2022 that is no longer disclosed as a pending matter in the company's Legal Proceedings item. Healthcare providers of this scale also carry standing exposure to fraud and abuse statutes, retroactive payor audits and state licensure rules across all ~33 states of operation. Financial leverage is moderate but real, with roughly ~$276M of term loan principal outstanding at SOFR plus ~3.00% maturing in December 2029 under a net leverage covenant, and TPG and Summit Partners together still hold about ~35.4% of the shares, an overhang that can weigh on the stock whenever those holders trim. Insider selling is routine but visible: the chief technology officer sold 42,067 shares for about ~$541K in September 2026. TDOC: Revenue has been roughly flat to declining for several years, and total revenue fell about 2% in 2025 and about 4% in Q2 2026, so the turnaround is about stabilization rather than growth. BetterHelp faces intense competition for therapy customers and rising acquisition costs that have compressed its profitability, and the insurance pivot is unproven at scale. Teladoc still reports GAAP net losses (a net loss of $38.9 million in Q2 2026 and about $177 million over the trailing twelve months) and carries debt, so the equity depends on cash flow and margin execution. Telehealth is crowded, with enterprise rivals, consumer-subscription players, and health plans building their own virtual care. The July 2026 cut to the BetterHelp outlook shows the cash-pay decline can run faster than planned, and the shares lost about 40% in the three months that followed.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell LFST or TDOC; figures are approximate and dated (as of November 2026). Verify current data before investing.